Vitrolife´s Interim Report, January - June 2002

Report this content

VITROLIFE´S INTERIM REPORT, JANUARY - JUNE 2002 · Net sales increased by 44 % and amounted to 62,5 MSEK (43,3 MSEK). · Gross profit increased by 113 % and amounted to 31,3 MSEK (14,7 MSEK). · Operating result was improved and amounted to -13,6 MSEK (-23,5 MSEK). · During May the subsidiary A-Life, Inc. in Newport Beach, California, USA was started. · After the expiry of this interim report Vitrolife has divested the sales rights of its products Ophthalin(TM) och Fermathron(TM) and the manufacturing plant in Scotland to Ioltech S.A. See attached interim report in Swedish with financial data in English (pdf format) Göteborg 15 August 2002 Vitrolife AB (publ) For information, please contact: Vitrolife: President and CEO Dr. Peter Svalander, tel +46 708 22 80 01 CFO Stefan Jacobsson, tel +46 708 22 80 10 Vitrolife Vitrolife's business mission is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs. Vitrolife intends to further expand the Company's production capacity to meet an expected increase in demand for its products, as well as strengthen its global market position as a leading company in the development of innovative cell and tissue technologies. Vitrolife believes that the number of procedures performed annually involving tissue and cell technologies will increase as new treatments are introduced and existing treatments are improved. In addition, Vitrolife expects that the regulation surrounding approval processes and quality control for its products will increase. Vitrolife aims to create competitive advantages from this regulation by meeting and exceeding expected future demands of regulatory authorities, ahead of the Company's competitors. Since it commenced its operations in 1993, Vitrolife has expanded rapidly. The Company currently has over 100 employees and sells its products in over 80 countries. During the latest five-year period, sales have steadily increased by and totalled more than SEK 100 million for the fiscal year 2001. The Vitrolife share is listed on the Stockholm Exchange (Stockholmsbörsen) O-list under the ticker VITR. ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The Full Report